The week’s Lancet has a great paper on the management of paracetamol overdose. A subject close to our heart at St.Emlyn’s following the recent changes to UK guidelines that have led far more people in the ‘treatment zone’. The increase in the number of patients getting treatment has inevitably led to an increase in the number of patients suffering the side effects of treatment. In the UK and Australia treatment consists of intravenous Acetylcysteine (Parvolex) in the following regimen (click on the figure to expand).
Since a change in 2012 we have become familiar with this regimen and it’s in daily use in most large EDs. In general it works well, but Acetylcysteine has a few problems.
- The dosing can cause confusion as it requires numerous calculations and I’ve seen people get it wrong (one of those people was me), so simplicity is a good thing.
- It takes a long time to complete…, 24 hours in fact and that’s a problem in the ED. Patients who have intentionally OD’d are often not declared ‘medically fit’ (discuss!!). Until the drug has completed the full 24 hours the psychiatry team may refuse to see the patient until they are signed off as ‘medically fit’ (again discuss what this means in this context!!!!). Patients therefore languish attached to a drip whilst arguably waiting for the management of the root cause of their problem. Shortening the waiting time would be a good thing.
- The drug has a number of side effects including vomiting, anaphylactoid reactions, rashes etc. This often interrupts treatment and it’s unpleasant for the patient. A lower incidence of side effects is good for everyone.
In other words, it’s not an easy drug to work with and so there are good basic arguments for simplifying the regime. In this week’s Lancet Bateman et al have done just that. Abstract below and please DO read the full paper as it is #FOAMed
So 217 patients in acute care settings were randomised to standard therapy (as described in the table above) or to a new accelerated regimen as below.
- 100mg/Kg in 100ml over 2 hours
- 200mg/Kg in 1000ml over 10 hours
- A dextrose infusion to act as a placebo for the next 12 hours.
In other words they have halved the time taken for treatment. They also randomised patients to receive Ondansetron or placebo prior to infusion. As vomiting is a significant side effect this is standard practice in some areas. Patients had to require treatment, so if subsequent testing (paracetamol levels) showed no need to continue treatment they were removed from the trial.
Glad you asked, as it’s interesting, clever and a little bit complex. The authors took a number of factors into account. They wanted to get roughly 4 equal groups, (ondansetron vs placebo and normal regimen vs new regimen gives four potential 2×2 combinations). They also wanted to make sure that they made sure that patients with a range of prognostic factors appeared in all of those 4 combinations. They used a technique called minimisation to do this which is quite smart. You can read the details in the link, but in essence minimisation allocates the next patient in a trial to the group which is least likely to cause an imbalance according to pre-existent factors. In this case they looked at paracetamol dose, known hepatotoxic risk factors and time. It’s a clever technique that perhaps we should see more of. Minimisation.
Good question, at first glance I thought this might tell us whether the new regime is better, but in all honesty (the authors are honest) it is too small to tell us whether the new regimen is better, worse or just the same. Greater numbers of patients would be required to do this. However, this trial can tell us about tolerance, acceptability and achievability. Their main outcomes were.
- 1. Incidence of vomiting/nausea.
- 2. Anaphylactoid reactions.
- 3. Greater than 50% rise in ALT levels
- 4. ALT >1000 IU/L
- 5. Subset analysis of micro RNA hepatic marker of toxicity
So we are not really looking at hard outcomes such as survival, requirement for transplantation, hepatic failure etc., but the authors are honest in this and don’t make those claims. What this can tell us is whether this might be worth looking at further.
Interesting and unexpected to be honest. I would have thought that a faster, shorter drug regimen would mean more side effects, but the opposite is true. For the primary outcome the lowest incidence of nausea vomiting was in the Ondansetron+new regimen group (roughly 26%), then the placebo+new regimen group (65%), then Ondanstron+ old (60%), then placebo+old (70%). This suggests that the difference was due to the new regimen rather than the Ondansetron, and those are clinically important differences.
Similarly there was a lower incidence of anaphylactoid reactions in the new regime groups.
So at first glance it looks as though the new regimen is better.
Not yet in my opinion. Firstly we don’t know enough about efficacy from this small trial, with only 110 patients in each group we cannot really determine the effectiveness for serious but rare outcomes. There was also some interesting data suggesting that Ondansetron might increase hepatic toxicity, though the numbers were really small and it remains an observation at this time. So, not enough to change tomorrow, but much to think about for the future. If I were a UK or International funding body I’d fund the big RCT that will give us the answer as to whether to change to a 12 hour regimen.
Paracetamol poisoning remains a real problem around the world. It’s common, potentially fatal and currently easy to get the dosing wrong. I like papers like this that challenge established practice and ask us to reconsider what we think we already know. If anyone wants to do the RCT and involve Virchester as a recruitment centre then get in touch, we have plenty of candidates .